South Korea’s CRO Ecosystem: KoNECT, MFDS and Korea-Based CROs
South Korea’s clinical-research environment brings together national infrastructure, regulatory oversight, research institutions and service providers. For sponsors, the practical issue is not whether a CRO is based in Korea, but whether it can demonstrate the country-specific capability required for the protocol.
Ecosystem overview
How Korea’s clinical-research ecosystem fits together
A clinical trial in South Korea is not delivered by one organization. National infrastructure, regulatory review, institutional ethics review, clinical sites, CROs and other service providers each perform different functions.
01 Why South Korea matters in clinical research Korea combines national infrastructure, established sites and a distinct regulatory environment.
South Korea can be relevant when the protocol and development strategy fit
South Korea has an established clinical-research environment involving national support infrastructure, designated clinical-trial institutions, experienced investigators and domestic as well as international service providers. Its relevance to a sponsor depends on the product, indication, site feasibility, regulatory strategy and wider APAC development plan.
Clinical institutions
Major academic medical centers and designated clinical-trial institutions support a range of study types.
National infrastructure
KoNECT provides ecosystem support, information resources, training and national clinical-trial programs.
Local execution
Korean-language capability, institution-specific workflows and country-level coordination may materially affect execution.
02 KoNECT and Korea’s national clinical-trial infrastructure KoNECT is a national support organization; K-CThub is one of its current digital resources.
What KoNECT does
The Korea National Enterprise for Clinical Trials (KoNECT) is a non-profit organization funded by Korea’s Ministry of Health and Welfare and forms part of the country’s clinical-trial support infrastructure. Its activities include ecosystem development, training, clinical-trial information and support programs.
K-CThub: an operational platform since January 2026
KoNECT officially launched the Korea Clinical Trials Hub (K-CThub) on 5 January 2026. The platform centralizes selected resources relevant to clinical-trial preparation and execution, including site, service-provider, study, investigator, regulatory and epidemiological information, together with feasibility and participant-recruitment support resources.
What K-CThub can support
Information discovery, feasibility preparation, site/provider searches and access to selected national clinical-trial resources.
What it does not replace
Sponsor due diligence, site qualification, CRO qualification, protocol-specific feasibility or regulatory judgment.
03 MFDS and the regulatory environment Regulatory review and institutional ethics review should be understood as distinct processes.
MFDS is Korea’s principal regulatory authority for relevant medicinal-product oversight
For applicable drug trials, the Ministry of Food and Drug Safety (MFDS) reviews the investigational clinical-trial application. Its IND review materials include the development plan, nonclinical information, relevant clinical information, protocol and Investigator’s Brochure.
| Function | Primary responsibility | What sponsors should clarify |
|---|---|---|
| Applicable regulatory / IND review | MFDS | Preparation, submission, tracking and response responsibilities. |
| Ethical / institutional review | Relevant institutional IRB | Document ownership, submission sequence and site responsibilities. |
| Site execution | Investigator and institution | Site readiness, delegation, training and local operational workflows. |
| Delegated sponsor activities | Sponsor / CRO according to allocation | Which activities are direct, subcontracted and subject to sponsor oversight. |
04 Hospitals, investigators and site infrastructure Korea has substantial clinical-site infrastructure, but suitability remains protocol-specific.
Site strength should be assessed at institution and investigator level
Korea includes major academic medical centers and numerous designated clinical-trial institutions. That provides a meaningful research base, but it does not guarantee recruitment, investigator availability or operational fit for a specific study.
- Relevant therapeutic and product experience.
- Current investigator interest and workload.
- Eligible patient population and referral pathways.
- Competing-study pressure.
- Contract and startup requirements.
- Site-team capacity and monitoring readiness.
05 Korea-based CROs and service capabilities Provider type and service scope vary; each capability should be verified independently.
Korea-based CROs are not one homogeneous provider group
The market can include domestic full-service CROs, specialist providers, biometrics or safety specialists, regulatory-focused providers, regional APAC CROs headquartered in Korea and global CROs with Korean operations.
| Service | Typical role | What the sponsor should verify |
|---|---|---|
| Clinical operations | Startup, project coordination, monitoring and closeout. | Korean staffing, relevant site experience and CRA coverage. |
| Regulatory support | MFDS-aware preparation and submission coordination. | Recent product-specific experience and qualified regulatory personnel. |
| Site management | Feasibility, investigator communication and performance follow-up. | Current institution experience and realistic site assumptions. |
| Data management | EDC support, data cleaning, query management and reconciliation. | Systems, controls, access, data location and direct vs subcontracted delivery. |
| Biostatistics / programming | Statistical planning, analysis and programming outputs. | Named expertise, standards and delivery location. |
| Pharmacovigilance | Safety workflow, SAE tracking, reconciliation and reporting support. | Responsibility boundaries, timelines and medical oversight. |
| Medical writing | Protocols, reports and submission-support documents. | Language capability, document standards and therapeutic experience. |
06 Sponsor value, governance and operational challenges Korea may fit a program when the protocol, sites, regulatory strategy and operating model align.
When Korea may be relevant to a sponsor
Korea may be considered when the protocol benefits from relevant Korean institutions or investigators, the product strategy includes Korea, or the study forms part of a broader APAC program. The decision should be based on protocol fit and evidence rather than general market reputation.
Potential sponsor value
Country-specific regulatory support, Korean-language operations, site coordination, local monitoring and sponsor-site communication.
Common operating challenges
Site competition, institution-level startup timelines, translation, regulatory coordination, recruitment feasibility and multi-vendor interfaces.
Governance matters when work is outsourced
Engaging a Korea-based CRO does not transfer away the sponsor’s ultimate responsibility for sponsor trial-related activities. Responsibilities should be documented, critical subcontractors understood and oversight proportionate to the study’s risks.
07 How to verify Korea-based CRO capability Evidence should show current country, team, service and site capability.
Evidence sponsors should request
| Evidence area | What to verify |
|---|---|
| Korea study history | Recent studies with comparable therapeutic/product and operational complexity. |
| Regulatory experience | Actual MFDS submission or support experience relevant to the product. |
| Sites | Recent work with appropriate institutions/investigators and evidence of current feasibility. |
| Local team | Named Korean personnel, roles, allocation and backup coverage. |
| Language | Korean/English communication and controlled-document workflows. |
| Monitoring | CRA coverage, site oversight, issue escalation and supervision. |
| Data / biometrics | Systems, standards, delivery location and subcontracting. |
| Safety | Case workflow, reconciliation, reporting support and medical oversight. |
| Vendors | Laboratories, technology, translation and other critical partners. |
| Governance | Reporting, escalation, senior oversight and sponsor interfaces. |
Questions worth asking
- Which Korean sites are realistic for this protocol?
- What recent Korea studies are most comparable?
- What MFDS activities has the proposed team supported?
- Which services are delivered directly?
- Which functions depend on subcontractors?
- How will Korean/English communication be controlled?
- What escalation route will apply to site and safety issues?
- How will the sponsor oversee critical activities?
08 Korea in APAC strategy and CRO peer groups Korea can be relevant nationally or within broader APAC development, depending on evidence and scope.
Korea should be interpreted in the right strategic context
A Korea-based CRO may operate primarily as a national provider, a specialist, a regional APAC provider or an emerging international CRO. Global company size should not automatically determine local relevance.
What could sustain Korea’s clinical-research relevance?
Structural factors include its national support infrastructure, regulated clinical-trial environment, designated research institutions, trained workforce and increasingly integrated clinical-trial information resources. Their relevance will continue to depend on the individual program.
09 FAQs, references and sponsor checklist Concise answers plus current official sources for Korea-specific verification.
Frequently asked questions
Use these answers as a starting point for Korea-specific CRO and clinical-development planning.
Why is South Korea relevant to clinical research?
South Korea has established clinical-trial institutions, national support infrastructure, a defined regulatory environment and experienced research sites. Its relevance still depends on the protocol, product and sponsor strategy.
What is KoNECT?
KoNECT is a national non-profit clinical-trial support organization funded by Korea’s Ministry of Health and Welfare. It supports infrastructure, training, information resources and ecosystem-development activities; it is not a CRO.
What is K-CThub?
K-CThub is the Korea Clinical Trials Hub, launched by KoNECT in January 2026. It provides centralized access to selected site, investigator, service-provider, regulatory, epidemiological and feasibility resources.
What services can a Korea-based CRO provide?
Depending on the provider, services may include clinical operations, regulatory support, monitoring, site management, data management, biometrics, pharmacovigilance and medical writing. The actual direct service scope should be verified.
What should sponsors verify before selecting a Korea-based CRO?
Verify recent Korea study experience, MFDS capability, relevant site experience, named local staff, Korean/English communication, monitoring coverage, direct versus subcontracted services, data controls, safety workflows and governance.
Sponsor checklist
- Korea is justified by protocol and development strategy.
- Relevant institutions and investigators are feasible.
- MFDS and IRB responsibilities are mapped.
- Recent CRO country experience is verified.
- Named local team is reviewed.
- Direct and subcontracted services are understood.
- Language and document workflows are defined.
- Data and safety responsibilities are clear.
- Sponsor oversight model is documented.
